## SUPPLEMENTARY FIGURES




**Supplementary Figure 1. The forest plot of HR for OS in the weekly paclitaxel compared to 3-weeks paclitaxel regimen.** HR: hazard ratio; OS: overall survival.




**Supplementary Figure 2. The forest plot of HR for OS in the subgroup analysis based on carboplatin administration schedules.** HR: hazard ratio; OS: overall survival.




**Supplementary Figure 3. The forest plot of HR for OS in the subgroup analysis based on the DDR of paclitaxel.** HR: hazard ratio; OS: overall survival; DDR: dose density ratio.




**Supplementary Figure 4. The forest plot of HR for OS in the subgroup analysis based on ethnic differences of included populations.** HR: hazard ratio; OS: overall survival.




**Supplementary Figure 5. The forest plot of OR for non-hematologic toxicities (vomiting, nausea, infection, fatigue, dyspnea, diarrhea, constipation, arthritis, alopecia, and neuropathy) in the weekly paclitaxel compared to 3-weeks paclitaxel regimen.** OR: odds ratio.




**Supplementary Figure 6. The funnel plots for publication bias.** (**A**) for articles measuring the incidence of OS. (**B**) for articles measuring the incidence of PFS. (**C**) for articles measuring the incidence of ORR. The vertical blue dotted line and two oblique blue dotted lines represent the position of the combined effect value and its corresponding 95% confidence interval on the x-axis, respectively. The red arrows point to outlier studies. OS: overall survival; PFS: progression-free survival; ORR: overall response rate.




**Supplementary Figure 7. The forest plot of adjusted HR by trim and fill for PFS in the weekly paclitaxel compared to 3-weeks paclitaxel regimen.** HR: hazard ratio; PFS: progression-free survival.




**Supplementary Figure 8. The corrected forest plot of OR for response rate in the weekly paclitaxel compared to 3-weeks paclitaxel regimen.**